Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 17, 2022

SELL
$0.2 - $0.35 $1,400 - $2,450
-7,000 Reduced 27.8%
18,183 $0
Q2 2022

Jul 13, 2022

SELL
$0.18 - $0.29 $540 - $869
-3,000 Reduced 10.64%
25,183 $6,000
Q1 2022

May 12, 2022

BUY
$0.28 - $0.61 $2,800 - $6,100
10,000 Added 55.0%
28,183 $8,000
Q4 2021

Feb 03, 2022

SELL
$0.49 - $1.02 $2,940 - $6,120
-6,000 Reduced 24.81%
18,183 $10,000
Q1 2021

May 07, 2021

SELL
$1.25 - $2.77 $68 - $152
-55 Reduced 0.23%
24,183 $41,000
Q4 2020

Feb 04, 2021

BUY
$1.18 - $1.98 $3,486 - $5,850
2,955 Added 13.88%
24,238 $30,000
Q3 2020

Oct 29, 2020

BUY
$1.01 - $1.81 $6,060 - $10,860
6,000 Added 39.26%
21,283 $30,000
Q2 2020

Jul 27, 2020

BUY
$1.03 - $1.69 $15,741 - $25,828
15,283 New
15,283 $18,000
Q4 2018

Feb 05, 2019

SELL
$2.13 - $4.8 $29,155 - $65,702
-13,688 Closed
0 $0
Q3 2018

Nov 02, 2018

BUY
$2.6 - $4.6 $2,600 - $4,600
1,000 Added 7.88%
13,688 $0
Q2 2018

Aug 10, 2018

SELL
$2.13 - $4.2 $4,260 - $8,400
-2,000 Reduced 13.62%
12,688 $0
Q4 2017

Feb 22, 2018

BUY
$1.75 - $5.5 $4,725 - $14,850
2,700 Added 22.52%
14,688 $0
Q3 2017

Nov 07, 2017

BUY
$2.9 - $4.6 $1,479 - $2,346
510 Added 4.44%
11,988 $55,000
Q2 2017

Aug 08, 2017

BUY
N/A
11,478
11,478 $25,000

About ACELRX PHARMACEUTICALS INC


  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.